Literature DB >> 33718942

Modern management of genitourinary syndrome of menopause.

Ana Sofia Da Silva1, Georgina Baines1, George Araklitis1, Dudley Robinson1, Linda Cardozo1.   

Abstract

The genitourinary syndrome of menopause (GSM) is the accepted term used to describe the broad spectrum of genitourinary tract symptoms and signs caused by the loss of endogenous sex steroids that occurs at the time of and after the menopause. Global improvements in healthcare have resulted in an ageing population. Today, women are spending 40% of their lives in the postmenopausal state, and with 50-70% of postmenopausal women reporting symptomatic GSM, safe and efficacious treatments are needed for this troublesome condition. This article reviews current evidence for non-pharmacological and pharmacological treatments with a focus on novel and minimally invasive procedures such as energy-based devices (CO2 laser, YAG laser), hyaluronic acid, dehydroepiandrosterone, and selective oestrogen receptor modulators. Copyright:
© 2021 Cardozo L et al.

Entities:  

Keywords:  CO2 laser; DHEA; Er:YAG; GSM; Genitourinary syndrome of menopause; Hyaluronic acid; Intrarosa; Laser; Lubricants; Moisturisers; Oestrogen; Orasterone; Ospemifene; Osphena; Ovestin; SERMS; Vagifem

Year:  2021        PMID: 33718942      PMCID: PMC7946389          DOI: 10.12703/r/10-25

Source DB:  PubMed          Journal:  Fac Rev        ISSN: 2732-432X


  59 in total

1.  Vaginal Health: Insights, Views & Attitudes (VIVA) - results from an international survey.

Authors:  R E Nappi; M Kokot-Kierepa
Journal:  Climacteric       Date:  2011-12-14       Impact factor: 3.005

2.  2016 IMS Recommendations on women's midlife health and menopause hormone therapy.

Authors:  R J Baber; N Panay; A Fenton
Journal:  Climacteric       Date:  2016-02-12       Impact factor: 3.005

Review 3.  Laser therapy for the restoration of vaginal function.

Authors:  Marco Gambacciani; Santiago Palacios
Journal:  Maturitas       Date:  2017-02-04       Impact factor: 4.342

4.  Position of the Spanish Menopause Society regarding vaginal health care in postmenopausal women.

Authors:  Rafael Sánchez-Borrego; Montserrat Manubens; Maria Concepción Navarro; Ma Jesús Cancelo; Estanislao Beltrán; Magda Duran; Teresa Orte; Laura Baquedano; Santiago Palacios; Nicolás Mendoza
Journal:  Maturitas       Date:  2014-03-24       Impact factor: 4.342

5.  Vulvar vestibular effects of ospemifene: a pilot study.

Authors:  Filippo Murina; Stefania Di Francesco; Silvia Oneda
Journal:  Gynecol Endocrinol       Date:  2018-01-15       Impact factor: 2.260

6.  Genitourinary syndrome of menopause. Prevalence and quality of life in Spanish postmenopausal women. The GENISSE study.

Authors:  E Moral; J L Delgado; F Carmona; B Caballero; C Guillán; P M González; J Suárez-Almarza; S Velasco-Ortega; C Nieto
Journal:  Climacteric       Date:  2018-02-07       Impact factor: 3.005

7.  Efficacy of vaginal therapies alternative to vaginal estrogens on sexual function and orgasm of menopausal women: A systematic review and meta-analysis of randomized controlled trials.

Authors:  Eleni Pitsouni; Themos Grigoriadis; Athanasios Douskos; Margarita Kyriakidou; Matthew E Falagas; Stavros Athanasiou
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2018-08-06       Impact factor: 2.435

Review 8.  Vaginal rejuvenation using energy-based devices.

Authors:  Cheryl Karcher; Neil Sadick
Journal:  Int J Womens Dermatol       Date:  2016-06-21

Review 9.  Local oestrogen for vaginal atrophy in postmenopausal women.

Authors:  Anne Lethaby; Reuben Olugbenga Ayeleke; Helen Roberts
Journal:  Cochrane Database Syst Rev       Date:  2016-08-31

10.  Overall Safety of Ospemifene in Postmenopausal Women from Placebo-Controlled Phase 2 and 3 Trials.

Authors:  James A Simon; Corrado Altomare; Susannah Cort; Wei Jiang; JoAnn V Pinkerton
Journal:  J Womens Health (Larchmt)       Date:  2017-10-24       Impact factor: 2.681

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.